NEW YORK, Aug. 22, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Foundation Medicine, Inc. (NASDAQ:FMI) who purchased shares between February 26, 2014 and November 3, 2015. The action, which was filed in the USDC for the District of Massachusetts, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose material information regarding: (1) the reimbursement process and likelihood of coverage for Foundation’s tumor tests by Medicare; and (2) the Company’s financial guidance. As a result of these false statements, Foundation common stock traded at artificially inflated prices during the Class Period.
On July 29, 2015, the Company disclosed that it was not making the strides obtaining coverage it had claimed to have been making during the Class Period, and that Foundation would receive no Medicare payments in 2015 for its tumor profiling tests due to a delay in receiving a local coverage determination from its regional Medicare Administrative Contractor. As a result of the delay, the Company slashed its 2015 financial guidance, which, unbeknownst to investors, was based on an assumption that Medicare approval was going to be obtained in 2015. Then, on November 3, 2015, the Company disclosed a further revision to the already reduced number of clinical tests it expected to report for 2015.
Shareholders have until September 26, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/foundation-medicine-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 



